Semaglutide for treating type 2 diabetes (ID1450)Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dulaglutide for treating type 2 diabetes [ID1451]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sotagliflozin for treating type 2 diabetes [ID1657]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition [ID6259]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ranibizumab port delivery system for treating diabetic macular oedema TS ID 10549Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Insulin icodec for treating type 1 and type 2 diabetes TS ID 11770Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC